Project Details
Projekt Print View

Effect of inhaled Nitric Oxide on bacterial burden and disease outcome in a murine model of Klebsiella pneumonia

Subject Area Anaesthesiology
Term from 2019 to 2020
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 434095988
 
Final Report Year 2021

Final Report Abstract

In vivo dose-response studies confirmed that efficacy of nitric oxide (NO) treatment against Klebsiella pneumoniae (Kp) is dose- and time dependent. Although lower NO concentrations (10-40ppm) were effective for the treatment of Pseudomonas aeruginosa, we did not observe any beneficial effect of low dose (80ppm) NO for Kp infections in mice. High-dose NO reduced not only the viable bacteria in lung and spleen in Kp pneumonia, but also reduced inflammation in lung, assessed by neutrophil infiltration and myeloperoxidase level. This study was the first study of murine Kp infection showing an improvement in survival after the treatment with NO. We could demonstrate that one possible mechanism how NO exerts its bactericidal effect involves degradation of bacterial cell wall. In addition, NO also has an inhibitory effect on multiple drug resistant Kp strains. The results of the study will help to promote the research of nitric oxide as a potential adjunctive therapy for lung infections. Unexpected, the use of nitric oxide as an antimicrobial therapy has become widely known, due to clinical trials worldwide, searching for effective treatments against Sars-CoV-2 and COVID-19. Many clinical trials investigate the effect of NO on COVID-19. They are still ongoing and recruiting COVID-19 patients ranging from mild, spontaneous breathing to severely ill, intubated patients. Some of the nitric oxide studies on COVID-19 have already received some media coverage and probably if the results of the larger clinical studies are promising, nitric oxide might be widely used for the treatment of COVID-19 in the near future.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung